abt-199 has been researched along with plerixafor* in 1 studies
1 other study(ies) available for abt-199 and plerixafor
| Article | Year |
|---|---|
CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration.
Targeting the JAK/STAT and BCL2 pathways in patients with relapsed/refractory T cell acute lymphoblastic leukemia (T-ALL) may provide an alternative approach to achieve clinical remissions. Ruxolitinib and venetoclax show a dose-dependent effect on T-ALL individually, but combination treatment reduces survival and proliferation of T-ALL Topics: Benzylamines; Bridged Bicyclo Compounds, Heterocyclic; Central Nervous System; Cyclams; Hematopoietic Stem Cell Mobilization; Humans; Janus Kinase 1; Nitriles; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Receptors, CXCR4; Sulfonamides | 2021 |